Rebound. They announced that they will present research findings on the potential combination therapy of the injection drug Brinsidofvir with an immune checkpoint inhibitor for non-Hodgkin lymphoma resulting from collaborative research with the National Cancer Centre Singapore at the 66th American Society of Hematology Annual Meeting to be held in San Diego, California, from December 7th to 10th, receiving positive feedback. Non-Hodgkin lymphoma is a disease in which lymphocytes become cancerous, collectively known as B-cell lymphoma and T-cell/NK-cell lymphoma, accounting for over 90% of malignant lymphomas.
シンバイオ製薬---反発、併用療法の可能性について米国血液学会年次総会で公表
Shionogi Pharmaceutical - announces rebound, potential for combination therapy at the annual meeting of the American Society of Hematology.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated